Abstracts tagged "axial spondyloarthritis"

Abstract Number: 580 • 2019 ACR/ARP Annual Meeting
Association of Comorbidities with Disease Activity and Functional Impairment in Axial Spondyloarthritis: Results from a Nationwide Population-Based Study
Imke Redeker¹, Johanna Callhoff ², Falk Hoffmann ³, Hildrun Haibel ⁴, Joachim Sieper ⁴, Angela Zink ⁵ and Denis Poddubnyy ⁶, ¹Charité – Universitätsmedizin Berlin and German Rheumatism Research Centre, Berlin, Germany, ²German Rheumatism Research Centre, Berlin, Germany, ³Carl von Ossietzky University, Oldenburg, Germany, ⁴Charité Universitätsmedizin Berlin, Germany, Berlin, Germany, ⁵German Rheumatism Research Centre and Charité University medicine, Berlin, Germany, ⁶Charité - Universitätsmedizin Berlin and German Rheumatism Research Centre, Berlin, Germany, Berlin, Germany
Background/Purpose: Data on the prevalence of comorbidities and their association with disease activity and functional impairment in axial spondyloarthritis (axSpA) are scarce. The aim of…
Abstract Number: 612 • 2019 ACR/ARP Annual Meeting
Objective Ankylosing Spondylitis Physical Performance Index (ASPI) Is Highly Reliable and Feasible in Chilean Patients
Rianne van Bentum¹, Sebastian Ibáñez Vodnizza ², Francisca Valenzuela Aldridge ², Maria Paz Poblete ³, Salima van weely ⁴, Marieke ter Wee ¹, Omar Valenzuela ⁵ and Irene van der Horst-Bruinsma ¹, ¹Amsterdam Rheumatology and immunology Center, Rheumatology, Amsterdam University Medical Center location VUmc, Amsterdam, Amsterdam, Netherlands, ²Rheumatology dpt., Clínica Alemana - UDD Medicine faculty, Santiago, Chile, ³Rheumatology dpt., Facultad de Medicina Clinica Alemana - UDD, Santiago, Region Metropolitana, Chile, ⁴Orthopedics, Rehabilitation and Physical Therapy dpt., Leiden University Medical Center, Leiden, Netherlands, ⁵Facultad de Medicina Clinica Alemana -UDD, Santiago, Region Metropolitana, Chile
Background/Purpose: In axial spondyloarthritis (axSpA), preservation of physical functioning is an important treatment goal and is usually assessed with the patient-reported BASFI questionnaire. The Ankylosing…
Abstract Number: 936 • 2019 ACR/ARP Annual Meeting
Earlier Treatment of Non-Radiographic Axial Spondyloarthritis with Certolizumab Pegol Results in Improved Clinical and Patient-Reported Outcomes
Jonathan Kay¹, Lianne Gensler ², Atul Deodhar ³, Walter P. Maksymowych ⁴, Nigil Haroon ⁵, Simone Auteri ⁶, Natasha de Peyrecave ⁷, Thomas Kumke ⁸, Bengt Hoepken ⁹, Lars Bauer ⁹ and Martin Rudwaleit ¹⁰, ¹UMass Memorial Medical Center and University of Massachusetts Medical School, Worcester, MA, ²University San Francisco California, San Francisco, CA, ³Oregon Health & Science University, Portland, OR, ⁴University of Alberta/CARE ARTHRITIS, Edmonton, AB, Canada, ⁵Toronto Western Hospital, Krembil Research Institute, University of Toronto, Toronto, ON, Canada, ⁶UCB Pharma, Brussels, Belgium, ⁷UCB Pharma, Slough, United Kingdom, ⁸UCB Pharma, Monheim, Germany, ⁹UCB Pharma, Monheim am Rhein, Germany, ¹⁰Klinikum Bielefeld, Charité Berlin, Gent University, Bielefeld, Germany
Background/Purpose: Patients (pts) with axial spondyloarthritis (axSpA) often experience delayed diagnosis, which can lead to treatment delay. However, there are indications that earlier treatment with…
Abstract Number: 1501 • 2019 ACR/ARP Annual Meeting
Ixekizumab: 52-Week Efficacy and Safety in Radiographic Axial Spondyloarthritis Patients with Prior Inadequate Response/Intolerance to Tumor Necrosis Factor Inhibitors
Maxime Dougados¹, Joachim Sieper ², Xenofon Baraliakos ³, Filip Van den Bosch ⁴, Walter P. Maksymowych ⁵, Joerg Ermann ⁶, Xiaoqi Li ⁷, Gaia Gallo ⁸, Hilde Carlier ⁷ and Lianne Gensler ⁹, ¹Hôpital Cochin, Paris, France, ²Charité Universitätsmedizin Berlin, Germany, Berlin, Germany, ³Rheumazentrum Ruhrgebiet-Ruhr-University Bochum, Herne, Germany, Herne, Germany, ⁴Ghent University Hospital, Ghent, Belgium, ⁵University of Alberta, Edmonton, AB, Canada, ⁶Brigham and Women's Hospital, Boston, ⁷Eli Lilly and Company, Indianapolis, ⁸Eli Lilly and Company, Indianapolis, IN, ⁹University San Francisco California, San Francisco, CA
Background/Purpose: Week 16 results from COAST-W (NCT02696798) showed that ixekizumab (IXE) was superior to placebo (PBO) in improving the signs and symptoms of active radiographic…
Abstract Number: 1822 • 2019 ACR/ARP Annual Meeting
6 and 12-month Drug Retention Rates and Treatment Outcomes in 941 Patients with Axial Spondyloarthritis Treated with Secukinumab in Routine Clinical Practice in 12 European Countries in the EuroSpA Research Collaboration Network
Brigitte Michelsen¹, Johan Askling ², Catalin Codreanu ³, Herman Mann ⁴, Anne Gitte Loft ⁵, Manuel Pombo-Suarez ⁶, Ziga Rotar ⁷, Tore Kvien ⁸, Maria José Santos ⁹, Anna Mari Hokkanen ¹⁰, Florenzo Iannone ¹¹, Bjorn Gudbjornsson ¹², Fatos Onen ¹³, Lennart Jacobsson ¹⁴, Ruxandra IONESCU ¹⁵, Karel Pavelka ⁴, Carlos Sánchez-Piedra ¹⁶, Matija Tomsic ¹⁷, Joe Sexton ¹⁸, Helena Santos ¹⁹, Jenny Österlund ²⁰, Alberto Cauli ²¹, Arni Jon Geirsson ²², Servet Akar ²³, Adrian Ciurea ²⁴, Gareth Jones ²⁵, Irene van der Horst-Bruinsma ²⁶, Cecilie Heegaard Brahe ²⁷, Stylianos Georgiadis ²⁸, Lykke Midtbøll Ørnbjerg ²⁷, Mikkel Østergaard ²⁹ and Merete Lund Hetland ³⁰, ¹Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet Glostrup, Denmark/ Hospital of Southern Norway Trust, Kristiansand, Norway/ Diakonhjemmet Hospital, Oslo, Norway, Oslo, Norway, ²Karolinska Institutet, Stockholm, Sweden, ³Center of Rheumatic Diseases, University of Medicine and Pharmacy, Bucharest, Romania., Bucharest, Romania, ⁴Institute of Rheumatology, Department of Rheumatology, 1st Faculty of Medicine, Prague, Czech Republic, Prague 2, Czech Republic, ⁵Department of Rheumatology, Aarhus University Hospital, Aarhus, Denmark, Århus, Denmark, ⁶Unit Research, Spanish Society of Rheumatology, Madrid, Spain, ⁷UMC LJUBLJANA, DPT. OF RHEUMATOLOGY, LJUBLJANA, Slovenia, ⁸Diakonhjemmet Hospital, Dept. of Rheumatology / University of Oslo, Faculty of Medicine, Oslo, Norway, ⁹Rheumatology department, Hospital Garcia de Orta, Almada, Portugal, ¹⁰Helsinki University Hospital, Helsinki, Finland, ¹¹Department of Emergency and Transplantation , Rheumatology Unit, University Hospital of Bari, Bari, Italy., Bari, Italy, ¹²Centre for Rheumatology Research, Landspitali and Faculty of Medicine, University of Iceland, Reykjavik, Iceland, ¹³Dokuz Eylul University School of Medicine, Division of Rheumatology, İzmir, Turkey, ¹⁴Dept of Rheumatology and Inflammation Research, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Sweden,, Gothenburg, Sweden, ¹⁵SPITALUL CLINIC SFANTA MARIA, Bucharest, ¹⁶Research Unit, Spanish Society of Rheumatology, Madrid, Spain, ¹⁷Department of Rheumatology, University Medical Center Ljubljana, Slovenia, Ljubljana, Slovenia, ¹⁸Diakonhjemmet Hospital, Dept. of Rheumatology, Oslo, Norway, ¹⁹Instituto Português de Reumatologia (IPR), Lisbon, Portugal, ²⁰ROB-FIN registry, Helsinki University and Helsinki University Hospital, Helsinki, Finland, ²¹Universitá di Cagliari, Cagliari, Italy, ²²Centre for Rheumatology Research, University Hospital and Faculty of Medicine, Reykjavik, Iceland, ²³Izmir Katip Celebi University, Faculty of Medicine, Division of Rheumatology, İzmir, Turkey, ²⁴University Hospital Zürich, Zürich, Switzerland, ²⁵University of Aberdeen, Aberdeen, United Kingdom, ²⁶Amsterdam University Medical Center, Amsterdam, Netherlands, ²⁷Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet Glostrup, Denmark, Copenhagen, Denmark, ²⁸DANBIO registry and Copenhagen Center for Arthritis Research, Centre for Rheumatology and Spine Diseases, Rigshospitalet, Copenhagen, Denmark, ²⁹Copenhagen Center for Arthritis Research, University of Copenhagen, Copenhagen, Denmark, ³⁰DANBIO and Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Centre of Head and Orthopaedics, Rigshospitalet, Copenhagen, Denmark
Background/Purpose: Secukinumab is a fully human IgG1 monoclonal antibody targeting interleukin-17A. There is a lack of real-life evidence on secukinumab retention rates and treatment outcomes…
Abstract Number: 582 • 2019 ACR/ARP Annual Meeting
Rheumacheck – Spondyloarthritis: Comprehensive Fast-track Diagnosis Program. What Benefits Does It Offer in a Developing Country?
Einer Sanchez Prado¹, Alvaro Ruta ², Jessica Torres Chichande ², Santiago Ruta ³, Sebastian Magri ², Facundo Salvatori ² and Rodrigo Garcia Salinas ², ¹Hospital Italiano de La Plata, La Plata, ²Hospital Italiano de La Plata, La plata, Buenos Aires, Argentina, ³Rheumatology Department, Hospital San Martín de La Plata and Rheumatology Unit, Hospital Italiano de La Plata, Argentina., La Plata, Argentina
Background/Purpose: In our region, the lack of knowledge, timely referral and access to laboratory tests and images are the main causes in the diagnostic delay…
Abstract Number: 615 • 2019 ACR/ARP Annual Meeting
Effects of NSAIDs and TNF Inhibitors on Cardiovascular Events in Ankylosing Spondylitis: A Systematic Review and Meta-Analysis
Paras Karmacharya¹, Ravi Shahukhal ², Cynthia Crowson ³, M.Hassan Murad ⁴, Pragya shrestha ⁵, Delamo Bekele ⁶, Kerry Wright ⁴, John Davis ⁴ and Maureen Dubreuil ⁷, ¹Reading Hospital, Mayo Clinic, Rochester, ²Lakes Regional General Hospital, Laconia, NH, ³Mayo Clinic Rochester, Rochester, ⁴Mayo Clinic, Rochester, MN, ⁵Mayo Clinic. Rochester, MN, Rochester, MN, ⁶Mayo Clinic Rochester, Rochester, MN, ⁷Boston University School of Medicine, Boston, MA
Background/Purpose: Most studies show a significantly higher risk of myocardial infarction [MI] (odds ratio [OR] = 1.60) and stroke (OR = 1.50) in ankylosing spondylitis (AS)…
Abstract Number: 938 • 2019 ACR/ARP Annual Meeting
TNF Inhibitors Reduce Spinal Radiographic Progression in Axial Spondyloarthritis by Mechanisms Associated with but Also Independent of Disease Activity
Alexandre Sepriano¹, Sofia Ramiro ², Stephanie Wichuk ³, Praveena Chiowchanwisawakit ⁴, Terrie MacCosham ³, Joel Paschke ⁵, Désirée van der Heijde ¹, Robert B.M. Landewé ⁶ and Walter Maksymowych ⁷, ¹Leiden University Medical Center, Leiden, Netherlands, ²Leiden University Medical Center and Zuyderland Medical Centre, Leiden, Netherlands, ³University of Alberta, Edmonton, Canada, ⁴Mahidol University, Bangkok, Thailand, ⁵CARE Arthritis, Edmonton, Canada, ⁶Amsterdam University Medical Center, Amsterdam, Netherlands, ⁷University of Alberta and CARE Arthritis, Edmonton, Canada
Background/Purpose: Recent observational data suggest that TNFi reduce spinal radiographic progression in radiographic axial spondyloarthritis (r-axSpA) mostly by inhibiting disease activity1. Yet, resolution on the…
Abstract Number: 1507 • 2019 ACR/ARP Annual Meeting
Certolizumab Pegol Improves Work and Household Productivity and Social Participation over 1 Year of Treatment in Patients with Non-Radiographic Axial Spondyloarthritis
Atul Deodhar¹, Lianne Gensler ², Jonathan Kay ³, Walter P. Maksymowych ⁴, Nigil Haroon ⁵, Robert B.M. Landewé ⁶, Martin Rudwaleit ⁷, Stephen Hall ⁸, Lars Bauer ⁹, Bengt Hoepken ⁹, Natasha de Peyrecave ¹⁰, Thomas Kumke ¹¹ and Désirée van der Heijde ¹², ¹Oregon Health & Science University, Portland, OR, ²University San Francisco California, San Francisco, CA, ³UMass Memorial Medical Center and University of Massachusetts Medical School, Worcester, MA, ⁴University of Alberta/CARE ARTHRITIS, Edmonton, AB, Canada, ⁵Toronto Western Hospital, Krembil Research Institute, University of Toronto, Toronto, ON, Canada, ⁶Amsterdam University Medical Center, Amsterdam, Netherlands, ⁷Klinikum Bielefeld, Charité Berlin, Gent University, Bielefeld, Germany, ⁸Monash University and Emeritus Research, Melbourne, Australia, ⁹UCB Pharma, Monheim am Rhein, Germany, ¹⁰UCB Pharma, Slough, United Kingdom, ¹¹UCB Pharma, Monheim, Germany, ¹²Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: Patients (pts) with non-radiographic axial spondyloarthritis (nr-axSpA) report substantial impairment of productivity and daily activities due to the burden of their disease, similar to…
Abstract Number: 1854 • 2019 ACR/ARP Annual Meeting
The Utility of Fat Lesions in Close Relation to Other Structural MRI Lesions in the Sacroiliac Joints for Diagnosing Patients with Axial Spondyloarthritis
Sengül Seven¹, Mikkel Østergaard ², Lone Morsel-Carlsen ³, inge Juul Sørensen ¹, Birthe Bonde ⁴, Gorm Thamsborg ⁵, Jens Jørgen Lykkegaard ¹, Oliver Hendricks ⁶, Niklas Rye Jørgensen ⁷ and Susanne Juhl Pedersen ⁸, ¹Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Glostrup, Denmark, Glostrup, Denmark, ²Copenhagen Center for Arthritis Research, University of Copenhagen, Copenhagen, Denmark, ³Department of Radiology, Rigshospitalet, Glostrup, Denmark, Glostrup, Denmark, ⁴The Birthe Bonde Clinic of Physioterapy, Copenhagen, Denmark, Glostrup, Denmark, ⁵Center for Rheumatology and Spine Diseases, Rigshospitalet, Copenhagen, Denmark, Copenhagen, Hovedstaden, Denmark, ⁶Danish Hospital for Rheumatic Diseases, Sønderborg, Denmark, Sønderborg, Denmark, ⁷Department of Clinical Biochemistry, Rigshospitalet, Glostrup, Denmark, Glostrup, Denmark, ⁸Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Copenhagen, Denmark, Copenhagen, Hovedstaden, Denmark
Background/Purpose: Bone marrow edema on MRI of the sacroiliac joints (SIJ) plays an important role in the ASAS (Assessment of Spondyloarthritis International Society) classification criteria…
Abstract Number: 14 • 2019 ACR/ARP Annual Meeting
Sec16A Abnormalities Affect the Intracellular Trafficking of HLA-B27 in the Pathogenesis of Axial Spondyloarthritis
Ayantika Talukdar¹, Fanxing Zeng ², Zhenbo Zhang ¹ and Nigil Haroon ³, ¹University Health Network, Toronto, ON, Canada, ²University Health Network, Toronto, Canada, ³Toronto Western Hospital, Krembil Research Institute, University of Toronto, Toronto, ON, Canada
Background/Purpose: Axial Spondyloarthritis (AxSpA) is a chronic inflammatory arthritis, mainly affecting the axial skeleton. HLA-B27 confers the greatest genetic association in AxSpA. Exome sequencing in…
Abstract Number: 590 • 2019 ACR/ARP Annual Meeting
What Is the Impact of MRI on the Performance of the ASAS Classification Criteria in Patients Presenting with Undiagnosed Back Pain?
Walter P. Maksymowych¹, Raj Carmona ², Jonathan Chan ³, James Yeung ⁴, Sibel Zehra Aydin ⁵, Liam Martin ⁶, Ariel Masetto ⁷, Dianne Mosher ⁸, Olga Ziouzina ⁶, Stephanie Keeling ⁹, Sherry Rohekar ¹⁰, Rana Dadashova ¹¹, Joel Paschke ¹¹, Amanda Carapellucci ¹¹ and Robert Lambert ¹², ¹University of Alberta/CARE ARTHRITIS, Edmonton, AB, Canada, ²McMaster University, Hamilton, Canada, ³Artus Health Clinic, Vancouver, BC, Canada, ⁴Yeung Rheumatology, Vancouver, Canada, ⁵University of Ottawa Faculty of Medicine, Rheumatology,Ottawa Hospital Research Institute, 1967 Riverside Drive, Ottawa, ON, K1H 7W9, CANADA, Ottawa, Canada, ⁶University of Calgary, Calgary, Canada, ⁷Université de Sherbrooke, Sherbrooke, QC, Canada, ⁸University of Calgary, Calgary, AB, Canada, ⁹University of Alberta, Edmonton, AB, Canada, ¹⁰Western University, London, ON, Canada, ¹¹CARE Arthritis, Edmonton, Canada, ¹²University of Alberta, Edmonton, Canada
Background/Purpose: Classification criteria for axSpA comprise an imaging and a clinical arm, the former requiring radiographic or MRI evidence of sacroiliitis. Several cohorts have reported…
Abstract Number: 616 • 2019 ACR/ARP Annual Meeting
Association of Clinical and Radiographic Phenotype of Axial Spondyloarthritis and Skin Psoriasis: Results from the German Spondyloarthritis Inception Cohort
Mikhail Protopopov¹, Fabian Proft ², Joachim Sieper ², Hildrun Haibel ², Martin Rudwaleit ³ and Denis Poddubnyy ⁴, ¹Charité Universitätsmedizin Berlin, Germany, Berlin, Berlin, Germany, ²Charité Universitätsmedizin Berlin, Germany, Berlin, Germany, ³Klinikum Bielefeld, Charité Berlin, Gent University, Bielefeld, Germany, ⁴Charité - Universitätsmedizin Berlin and German Rheumatism Research Centre, Berlin, Germany, Berlin, Germany
Background/Purpose: Psoriasis is a common feature of axial spondyloarthritis (axSpA) occuring in approximately 10% of patients with axSpA. It has been presumed that such an…
Abstract Number: 1006 • 2019 ACR/ARP Annual Meeting
Vaspin rs35262691 Is Associated with Atherosclerotic Disease in Axial Spondyloarthritis Patients
Fernanda Genre¹, Javier Rueda-Gotor ¹, Sara Remuzgo-Martinez ¹, Veronica Pulito-Cueto ¹, Alfonso Corrales ¹, Veronica Mijares ¹, Leticia Lera-Gomez ¹, Virginia Portilla ¹, Rosa Expósito ², Cristina Mata ², Iván Ferraz-Amaro ³, Vanesa Hernández-Hernández ³, Santos Castañeda ⁴, Esther Vicente-Rabaneda ⁵, Cristina Fernández-Carballido ⁶, M. Paz Martínez-Vidal ⁷, David Castro-Corredor ⁸, Joaquín Anino-Fernández ⁸, Juan Quevedo-Abeledo ⁹, Carlos Rodríguez-Lozano ⁹, Ricardo Blanco ¹⁰, María Luz García-Vivar ¹¹, Eva Galíndez-Agirregoikoa ¹¹, Javier Llorca ¹², Raquel López-Mejías ¹ and Miguel Angel González-Gay ¹³, ¹Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, IDIVAL, Santander, Spain, Santander, Spain, ²Rheumatology Division, Hospital Comarcal de Laredo, Laredo, Spain, Laredo, Spain, ³Rheumatology Division, Hospital Universitario de Canarias, Tenerife, Spain, Tenerife, Spain, ⁴Rheumatology Department, Hospital Universitario de la Princesa, IIS-Princesa, Madrid, Spain, Madrid, Spain, ⁵Rheumatology Department, Hospital Universitario La Princesa, Madrid, Spain, ⁶Rheumatology Division, Hospital Universitario San Juan de Alicante, Alicante, Spain, Alicante, Spain, ⁷Rheumatology Division, Hospital General Universitario de Alicante, Alicante, Spain, Alicante, Spain, ⁸Rheumatology Division, Hospital General Universitario de Ciudad Real, Ciudad Real, Spain, Ciudad Real, Spain, ⁹Rheumatology Division, Hospital Universitario de Gran Canaria Dr. Negrín, Las Palmas de Gran Canaria, Spain, Las Palmas de Gran Canaria, Spain, ¹⁰Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, IDIVAL, Santander, Spain, ¹¹Rheumatology Unit, Basurto University Hospital, Bilbao, Spain, Bilbao, Spain, ¹²School of Medicine, University of Cantabria, and CIBER Epidemiología y Salud Pública (CIBERESP), Santander, Spain, Santander, Spain, ¹³Universidad de Cantabria and IDIVAL, Hospital Universitario Marqués de Valdecilla, Santander, Spain
Background/Purpose: Vaspin is a novel adipokine with insulin-sensitizing functions that exerts anti-inflammatory actions1,2. It has been associated with cardiovascular (CV) disease, CV risk factors and…
Abstract Number: 1509 • 2019 ACR/ARP Annual Meeting
Impact of Age and Disease Duration on the Response to IL-17A Inhibitor (Secukinumab) Treatment in Ankylosing Spondylitis: Pooled Results from the Phase 3 MEASURE Studies
Atul Deodhar¹, Philip Mease ², Paula Machado ³, Xiangyi Meng ³, Vibeke Strand ⁴ and Marina Magrey ⁵, ¹Oregon Health & Science University, Portland, OR, ²Swedish Medical Center/Providence St Joseph Health, and University of Washington, Seattle, WA, ³Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁴Division of Immunology/Rheumatology, Stanford University, Stanford, CA, ⁵Division of Rheumatology, The MetroHealth System and School of Medicine, Case Western Reserve University, Cleveland, OH
Background/Purpose: Ankylosing spondylitis (AS), a chronic inflammatory disease involving the sacroiliac joints and spine, is associated with pain, stiffness, disability, and reduced quality of life.1,2…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].